The UK faces a “rising” and unpredictable threat from Iran and the government must do more to counter it, Parliament’s intelligence and security committee has warned.
The call comes as it publishes the results of a major inquiry which examined Iranian state assassinations and kidnap, espionage, cyber attacks and the country’s nuclear programme.
The committee, which is tasked with overseeing Britain’s spy agencies, has raised particular concern over the “sharp increase” in physical threats posedagainst opponents of the Iranian regime in the UK.
“Iran poses a wide-ranging, persistent and unpredictable threat to the UK, UK nationals and UK interests,” said Lord Beamish, committee chair.
“Iran has a high appetite for risk when conducting offensive activity and its intelligence services are ferociously well-resourced with significant areas of asymmetric strength.”
He added: “Iran is there across the full spectrum of all the kinds of threats we have to be concerned with.”
The committee accuses the government of focusing on “crisis management” and “fire-fighting” with Iran, as well as on its nuclear programme, at the expense of other threats.
It says the national security threat from Iran requires more resourcing and a longer-term approach.
“Whilst Iran’s activity appears to be less strategic and on a smaller scale than Russia and China, Iran poses a wide-ranging threat to UK national security, which should not be underestimated: it is persistent and – crucially – unpredictable.”
On the physical threat to people living in the UK, the committee said it has significantly increased in pace and in number since the start of 2022.
It is focused at dissidents and other opponents of the Iranian regime, it said, adding there is also an increased threat “against Jewish and Israeli interests in the UK”.
There have been at least 15 attempts at murder or kidnap against British nationals or UK-based individuals since the beginning of 2022, the report found.
“The Homeland Security Group told us that the threat of physical attack on individuals in the UK is now ‘the greatest level of threat we currently face from Iran’, and comparable with the threat posed by Russia.”
But, the committee said, Iran does not view attacks on dissident, Jewish and Israeli targets in the UK as attacks on the UK. The report continues: “It rather sees the UK as collateral in its handling of internal matters – i.e. removing perceived enemies of the regime – on UK soil”.
The committee examines the policies, expenditure, administration and operations of UK intelligence organisations including MI5, MI6, and GCHQ.
Its 260-page report was published on Thursday as part of the committee’s inquiry into national security issues relating to Iran. It covers events up to August 2023, when the committee finished taking evidence.
It has previously been read by Prime Minister Sir Keir Starmer, who was sent a copy in March, and circulated among UK intelligence organisations to give them the opportunity to check accuracy and request redactions on national security grounds.
According to the committee, the government is required to provide its response within 60 days of publication.
A UK government spokesperson said the report “demonstrates the vital work” by security and intelligence agencies countering threats posed by states such as Iran.
“This government will take action wherever necessary to protect national security, which is a foundation of our Plan for Change.
“We have already placed Iran on the enhanced tier of the foreign influence registration scheme and introduced further sanctions against individuals and entities linked to Iran, bringing the total number of sanctions to 450.”
They thanked the committee and said the government will be responding fully.
CHENNAI: Swiss-pharma major Novartis AG said early this week that its pediatric malaria treatment, Coartem Baby, received regulatory approval from Swissmedic, Switzerland’s national medicines regulatory authority. This marks a milestone in global health, as this Novartis drug is the world’s first malaria treatment specifically developed for newborns and infants weighing between 2 and 5 kilograms.
Coartem Baby is a reformulation of the existing Coartem (artemether-lumefantrine) combination therapy. The new formulation was developed through a collaboration between Novartis and the Medicines for Malaria Venture (MMV), with support from the PAMAfrica consortium.
The clinical development program was co-funded by the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency. The approval was based on positive data from the Phase II/III CALINA study, which demonstrated that Coartem Baby has a pharmacokinetic profile suitable for infants under 5 kilograms and exhibits good efficacy and safety.
Global Health Impact
Malaria remains one of the world’s deadliest diseases, particularly among children under five years old in Africa. In 2023, there were an estimated 36 million pregnancies in 33 African countries where malaria is widespread, with about one in three mothers infected with malaria during pregnancy, raising the risk of transmission to their newborns.
It seems as if Dexter Morgan just cannot die. Remember the first Dexter finale 12 years ago? It climaxed with Morgan sailing his boat into an unsurvivable storm, a sure sign that our favourite serial-killing blood spatter analyst had finally met his end. But then the show lost its nerve and he somehow ended up in a postscript with a new job (lumberjack) and a new beard (unconvincing).
Next came 2021’s Dexter: New Blood, a series that was conceived as a definitive full stop for the character. That run ended with – spoiler alert – Dexter being shot dead by his son Harrison. However, now Morgan finds himself back yet again in Dexter: Resurrection, in which we quickly learn that this apparently fatal injury was merely a flesh wound.
“Well, you know, he didn’t get shot in the head,” shrugs Michael C Hall, who plays the titular character. Hall is attempting to explain Dexter’s latest miraculous comeback to me over Zoom – and if he’s getting tired of people like me telling him that they thought he was dead, he’s doing a pretty good job of hiding it.
Michael C Hall, Ntare Guma Mbaho Mwine, Jill Marie Lawrence and Sharon Hope in Dexter: Resurrection. Photograph: Zach Dilgard/Paramount+ with Showtime
This might be because it was his idea to bring Dexter back. “The conversation started as a result of my saying, ‘What if he didn’t die?’” he says breezily. “I can’t take credit for the whole scope of what we’re up to, but it was a notion that I casually floated. What if the end of New Blood was something that enabled Dexter to relinquish some burden that he’d been carrying for a long time?”
What changed his mind? “Time passing, perspective shifting, recognising what a wonderful thing it is to collaborate with this family,” he says. “And realising that how New Blood seemingly ended could be a way to move the character into a place he hadn’t quite earned until then.”
How well the character moves into that place remains to be seen. As we speak, the show is still in production, and only the first episode has been made available to view. Its early scenes might creak with tortured exposition – hardly surprising, given the near-impossible task of bringing someone back from the dead – but happily, the old Dexter magic is still present. There are callbacks and cameos and grisly scenes of dismemberment. Better yet, the season promises all kinds of warped bonding between Dexter (a serial killer) and Harrison (his son and, until quite recently, murderer).
“Harrison has been through a lot, and has a sense of maturity that he didn’t have when we first met him in New Blood,” says Hall. “Dexter initially is very much compelled to check in on his son, but is also daunted by the proposition of making contact, because he’s afraid his son will reject him, or won’t want him, or will wish he’d stayed dead. But I think finding themselves on the other side of this traumatic event will result in both Dexter and his son growing up a little bit.”
Uma Thurman as Charley in Dexter: Resurrection. Photograph: Zach Dilgard/Paramount+ with Showtime
We also have a new fleet of faces to look forward to. Peter Dinklage and Uma Thurman are there, respectively playing a billionaire venture capitalist and his head of security, plus Neil Patrick Harris, Eric Stonestreet, Krysten Ritter and David Dastmalchian will all appear as villains invited to what sounds an awful lot like an international murder convention. “Dexter sort of trips into a literal and figurative invitation to a gathering of unsavoury …” teases Hall of this year’s plot, before trailing off for fear of spoiling anything. “Actually, I’m not sure how much I can say. But it’s really validating and gratifying, the fact that the show remains compelling to the kinds of actors who’ve agreed to join us.”
Perhaps another reason for Hall’s willingness to return was this year’s Dexter: Original Sin. A prequel series that took the form of Dexter’s life flashing before his eyes post-shooting, Original Sin didn’t star Hall (although he provided the voiceover), instead casting Shadow and Bone’s Patrick Gibson as Morgan.
I had wondered if the simple envy of seeing someone else do his job drove Hall back to Dexter, but apparently this wasn’t the case. “I thought it was interesting, once all those blanks had been filled in, to find the character on the other side of it,” he says. “But it was weird to see Patrick embody some of what had evolved as Dexter’s characteristic ways of being. Yes, it’s very strange. In fact, at one point I was like, when I go back to work, I gotta make sure I’m not just doing a Patrick Gibson impression.”
Peter Dinklage in Dexter: Resurrection. Photograph: Zach Dilgard/Paramount+ with Showtime
There will be more Original Sin (a second season was greenlit this spring): another sign of what looks like an ever-expanding Dexterverse. There’s likely to be continued Resurrection – more about that shortly – plus there are rumours of a spin-off focused on John Lithgow’s Trinity Killer. All of which perhaps underlines how much better television as a whole was in Dexter’s heyday.
The original Dexter came out in 2006 at the height of the golden age of TV, with its focus on anguished male antiheroes. Much has been made lately of the demons that plagued James Gandolfini before his death, some attributed to the burden of having to play a character as dark as Tony Soprano for so many years. As Dexter, though, Hall played a serial killer who had to murder and dismember countless people. Did the darkness of the role ever get to him?
Michael C Hall on satellite radio station Sirius XM in New York this week. Photograph: Cindy Ord/Getty Images for SiriusXM
“I think Dexter exists in a world that is, to some degree, dialled away from reality,” he explains. “It’s fantastic in its way and, because of that fantastical element, maybe it doesn’t play the same trick on me that it might otherwise. And you know, as intense as it might be to convey someone who’s wrestling with such formidable darkness, it’s maybe therapeutic. You can endow these victims with whatever it is you’d like to do away with in your own world. Maybe I’m a healthier person for having done all this.”
There is also the question of how comfortable Hall is with returning to the same character over and over again. After all, Dexter aside, his stock in trade is playing a dizzying breadth of characters – he was JFK in The Crown, the Emcee in Cabaret, the lead in David Bowie’s Lazarus musical, a professional bowler in a Tim Robinson-written episode of Documentary Now!. Yet he keeps being drawn back to Dexter. Surely he must be aware that this will be the first line of his obituary.
“I mean, what are you going to do?” he shrugs. “That’s the way it’s unfolded. Whether I were to do more of this or not, I think that would remain the case, and it’s OK. None of it fundamentally matters anyway. But it’s been really fun. Being able to work as an actor feels like getting away with something. Being able to work as an actor while playing a character like Dexter feels exponentially so. I feel very lucky to have gotten away with this.”
A knottier question to bring up is the internet. As well as the initial finale routinely being brought up as one of the worst in television history, a Hollywood Reporter interview with showrunner Clyde Phillips last year suggested that fans weren’t exactly happy with how New Blood ended, either. “The internet hated it,” Phillips said bluntly. With this in mind, I ask Hall if he keeps up with the ins and outs of reactions to the show.
“No, that would make me crazy,” he replies. “But some fans found the notion of Dexter surviving more plausible than him dying. There’s something about the character that people just don’t want to see him die. They don’t want to see his agency extinguished.”
Watch a trailer for Dexter: Resurrection
The good news for these fans is that Dexter: Resurrection is intended to be a long-running affair. The introduction of so many guest stars this season is designed to trickle out across several years, or, as Phillips put it to USA Today, the duration of the comeback is “up to Michael”.
“Well, I guess it’s hard for Dexter to happen if I’m not there,” Hall sighs when I mention this to him. Does this mean he would like Resurrection to run and run? Is there a world where it could end up rivalling the length of the original series? “That sounds insane,” he laughs. “All I can say is that I don’t think we resolve things at the end of this season, and we’ve done it with the reasonable expectation that there will be more to come.”
So you don’t get shot at the end of this one? “We still have two and a half weeks left of filming, and I suppose someone could present some new pages to me,” he smiles. But what would be the point? After all, Dexter Morgan cannot die. And we should all be thankful for that.
“The Salt Path is an unflinchingly honest, inspiring and life-affirming true story,” reads the description of Raynor Winn’s bestselling memoir on its publisher Penguin Random House’s website.
Which is unfortunate wording if accusations made at the weekend turn out to be true: an investigation by the Observer alleged that the 2018 book – which has recently been adapted into a film starring Gillian Anderson and Jason Isaacs – is not all that it seems. Winn writes in The Salt Path that she and her husband, Moth, had their home repossessed due to an investment in a friend’s company that went on to fail. With nowhere to live, as she tells it, the couple decided to walk the length of the South West Coast Path, wild camping along the way and relying on the kindness of strangers. The Observer piece suggests Winn’s account of becoming homeless is untruthful, and reports that she took £64,000 from her former employer. It also questions the legitimacy of Moth’s diagnosis with the neurological condition corticobasal degeneration (CBD), a core part of the memoir.
Winn’s immediate response called the article “highly misleading”, adding: “We are taking legal advice and won’t be making any further comment at this time.” She stood by her book being “the true story of our journey”. Still, after the report, PSPA, a charity that supports people with CBD and formerly worked with Winn and her husband, terminated its relationship with the couple.
On Wednesday, Winn published a more detailed statement, defending her book’s truthfulness and giving more detail about the events that led to the couple losing their home. She also provided medical letters addressed to her husband in defence of allegations relating to his illness.
This is not the first time a much-hyped memoir has come up against accusations of lying. Belgium-born Misha Defonseca’s 1997 book about how she was raised by wolves during the second world war turned out to be completely fabricated. Love and Consequences by Margaret B Jones, which was sold on release in 2008 as the true story of the author’s experience growing up as a mixed-race foster child in South Central Los Angeles, turned out to have been written by Margaret Seltzer, a white, privately educated woman who grew up with her biological family.
James Frey at the Union Chapel, London, in 2011. Photograph: David Levene/The Guardian
Perhaps the most famous instance is James Frey’s A Million Little Pieces, a 2003 memoir of drug addiction and alcoholism that, after being championed by Oprah Winfrey in 2005, shot to the top of the New York Times bestseller list and remained there for 15 weeks. It was billed as “brutally honest”, but later it came to light that chunks of the book had been made up. Winfrey in particular was furious with Frey, telling him it was difficult to talk to him when he came on her TV show to explain himself in 2006. “I feel duped,” she said. “But more importantly, I feel that you betrayed millions of readers.”
“How could they lie?” is a question many readers ask when a memoir they love is proved to be untrue. But there’s another question that needs to be answered, too: how could the author get awaywith it? How did they manage to get their lies past an agent and multiple editors, all the way into a published book labelled as a true story?
The short answer is that if someone is lying about their own life, it is often very difficult for others to tell. Dr Pragya Agarwal, the author of books including the 2021 memoir (M)otherhood and a teacher of memoir writing, says that a big part of writing nonfiction “is about trust between the writer and the reader. I am not really sure how someone’s life story can be factchecked in its entirety.”
Others say it is not the publisher’s role to investigate whether an author is telling the truth or not. Grace Pengelly is a freelance writer and editor who formerly worked as a nonfiction commissioning editor at HarperCollins. An editor’s role “is to help the author craft their story as compellingly and accurately as possible”, she says, and that requires believing in the writer. “Without a certain degree of trust from the outset, it is difficult for an editor and author to work with each other effectively.”
That doesn’t mean that memoirs are not fact-checked. “Prior to acquiring a memoir, a publisher would look into the background of the author and their story to see if it checks out,” says Pengelly. Any “question marks around the veracity of an author’s story would definitely be a reason why a publisher wouldn’t offer on a book”. But the research undertaken at this stage wouldn’t tend to involve checking whether someone was actually incarcerated for as long as they said they were (one of the major falsities in A Million Little Pieces), or whether a couple who claimed to be homeless actually owned a property in the south of France, as was alleged by the Observer regarding Winn and her husband (a property Winn has since described as an “uninhabitable ruin”).
Raynor and Moth Winn. Photograph: Jim Wileman/The Guardian
Finding out that kind of information might be possible only if publishers had specific teams dedicated to it. The publishing consultant and editor Katy Loftus, who previously worked for Penguin Random House, says she isn’t aware of any publishing houses with a factchecking department. “Other than top executive salaries, publishing is run on a shoestring. Books make much less money than people think,” she says. The big publishers have legal departments, “who will give an opinion on something flagged up to them by a commissioning editor, and occasionally do a complete legal read if requested”, she adds. But the main factchecking responsibility tends to fall to the commissioning editors, who are “responsible for hundreds of tasks” – from briefing book cover designers, to negotiating deals with authors, to managing teams of people. The editing itself “is often at the bottom of the list, and factchecking is only part of the editing process.”
Even when it comes to legal checks, the main concern is that a book doesn’t contain anything that might lead to the publisher being sued, rather than actually analysing the factual content, says Ian Bloom, a media lawyer who has worked in publishing. “To some extent, nobody much cares if they’ve got dates wrong and facts wrong, as long as there’s no legal implications.”
Bloom suspects that a number of celebrity memoirs in particular contain omissions or embellishments. “There’s no real harm done if they gloss over certain things in their lives,” he says, as long as it’s not defamatory to anyone else.
Aside from rare exceptions – such as when a group of readers successfully sued Frey’s publisher, claiming they were defrauded as they bought his book under the impression that it was true, and were refunded the cover price – publishers do not face serious material repercussions for lies told in memoirs. Reputational damage, meanwhile, is usually put on the author. “When an author signs a contract with a publisher, there are usually author covenants that include clauses about the truthfulness and integrity of the material to the best of the author’s knowledge and belief,” Bloom says. The publisher is then entitled to cancel that author’s contract, should a book’s veracity be called into question.
Of course, authors can get around this by writing “autobiographical fiction” rather than memoir: books such as the actor Carrie Fisher’s Postcards From the Edge, based on her own life but categorised as a novel, or the Booker-winning autofictional novel Shuggie Bain by Douglas Stuart, don’t come under fire for being made up, because we all know that’s what fiction is. So why didn’t authors like Frey turn their stories into novels? Perhaps the books wouldn’t have done as well marketed in that way – in a true-crime-obsessed world, we’re all familiar with the strength of desire for real stories.“Autofiction isn’t as well-established a genre as memoir,” Pengelly says. “So marketing teams face discrete challenges in framing and taking these stories to the public. A ‘true story’ has historically proved easier to build a campaign around.”
Once a book is out in the world, any inaccuracies tend to be spotted by journalists or academics – there is no regulator of the publishing industry equivalent to the Independent Press Standards Organisationand Ofcom for the media in the UK. With approximately 200,000 books published annually in the UK alone, “There’s no regulator on Earth who can read them all … it’s impossible,” Bloom says.
skip past newsletter promotion
after newsletter promotion
So how do we stop fake memoirs from being published? In light of the Salt Path allegations, Pengelly is sure publishers will be considering ways to avoid such a scenario coming up again. “If a narrative arc seems too neat and tidy to be true, perhaps it’s worth considering why, and employing a freelance factchecker to investigate,” she says.
Winn on her travels in south-west England.
The trouble is, neat and tidy narrative arcs are often exactly what many readers – and viewers of film adaptations – want. A memoir Pengelly worked on, Zig-Zag Boy by Tanya Frank, is about a mother coming to terms with her son’s experiences of psychosis. That book was a more modest commercial success than The Salt Path, but could it have been more of a hit if Frank had ended it with her son being “healed”, rather than with her accepting his altered state? Quite possibly. Triumph in the face of medical adversity is a seductive concept, as readers of Winn’s books will know from their stories of Moth’s ability to overcome the symptoms of his illness and undertake long walks.
Nic Wilson, whose memoir Land Beneath the Waves is about how the natural world helped her to navigate and accept her chronic illness, is disparaging of the “nature cure” trope we often see in popular books about health. It creates an unrealistic expectation that the order of events should be “diagnosis, illness, recovery. And I think readers come to expect that,” she says.
Clearly, authors may have something to gain by bowing to such expectations and embellishing or omitting certain facts of their life stories. But they also have the most to lose if lies in their books are exposed: they could have their publishing deal dropped, which might mean having to pay back their advance, and they risk no publisher wanting to be associated with them again.
Frey’s publisher, Nan Talese, was particularly aggrieved by the way her author’s reputation was attacked. Winfrey displayed “fiercely bad manners – you don’t stone someone in public, which is just what she did”, she told the Dallas Morning News at the time.
“Scandal has stalked memoir since the genre was invented,” Loftus says – an early example being the 1836 memoir Awful Disclosures of Maria Monk, a 20-year-old woman’s story of life in a Montreal convent, which was vilified as a hoax. “In practice the publicity rarely does more harm than good to the publisher, whereas an author’s life can be left in tatters.”
That’s not to say that they won’t continue to make money: A Million Little Pieces kept selling even in its second iteration, which had passages rewritten and contained a “note to the reader” addressing its inaccuracies. And whatever happens after the allegations made against Winn, having already sold more than 2m copies of The Salt Path, she has been made rich by this book and its sequels, and will continue to receive royalties for as long as people keep buying them.
The fact that there is money to be made – with very few legal repercussions – by telling the most marketable version of a story, rather than the true one, makes it difficult to believe that this controversy will be the last of its kind. After all, no memoir can be completely true. “Memories are fallible and selective; we always remember half-truths, and the story an author chooses to tell is only ever one story of a particular situation,” Agarwal says. “But what any reader wants to believe is that the story they have put their faith in is closest to the writer’s truth, that they have not been deliberately misled, that they have not been manipulated. This is essential.”
ISLAMABAD, Jul 10 (APP): Prime Minister Shehbaz Sharif on Thursday directed the relevant authorities to formulate a comprehensive plan to transform the Pakistan National Shipping Corporation (PNSC) into a shipping company of international standard.
The prime minister, chairing a meeting to review the restructuring, reforms, and performance of the PNSC, said that Pakistan’s shipping sector held vast potential for investment.
He directed that a comprehensive plan be prepared to encourage private investment in the shipping sector.
He called for steps to increase the number of ships and promote the competitive use of PNSC vessels for cargo movement to and from Pakistan.
Prime Minister Shehbaz advised to acquire the services of shipping experts and consultants to elevate PNSC to an international standard shipping company.
He expressed the hope that the reforms in the PNSC would not only save valuable foreign exchange currently being paid to international companies for shipping services but also create more employment opportunities for local seafarers.
The participants of the meeting were briefed on the PNSC’s operations, the current number of vessels in the PNSC, the annual cargo movement in Pakistan, and the future expansion plans for the organisation.
Federal ministers Ahad Khan Cheema, and Junaid Anwar Chaudhry, and relevant senior officials attended the meeting.
Ishtiaq Ahmed, APP’s Foreign Editor, leads coverage of the Prime Minister, President and Foreign Office, bringing over 20 years of journalism experience from local and international publications – Reach out at 03335293238/ ishtiaqrao@gmail.com/ X: ishtiaqrao
Triple-negative breast cancer (TNBC), an aggressive and hard-to-treat form of breast cancer, has long challenged researchers due to the absence of effective targeted therapies. Now, findings from Cold Spring Harbor Laboratory in New York State have revealed a potentially significant contributor to TNBC biology: a little-studied long non-coding RNA (lncRNA) known as LINC01235.
Breast cancer is among the most common malignancies in women worldwide, and TNBC accounts for approximately 10 to 15 percent of cases. It is disproportionately diagnosed in younger women and those of African American descent. While many forms of breast cancer benefit from targeted treatments, TNBC lacks such options, making basic research crucial.
The study was led by Professor David Spector and graduate student Wenbo Xu. They discovered that LINC01235, previously associated with gastric cancer, also plays a role in TNBC by regulating a gene called NFIB, which is already linked to this cancer subtype.
Using CRISPR gene-editing and antisense knockdown techniques in tumour organoids and cancer cells, the researchers showed that lowering LINC01235 levels suppressed NFIB expression and inhibited TNBC organoid growth. Further analysis suggested that this interaction affects the NOTCH signalling pathway, known to be involved in cancer cell proliferation.
The NOTCH signalling pathway is a fundamental cell communication system that regulates how cells develop, differentiate, and interact with their environment. It is evolutionarily conserved and plays a crucial role in embryonic development, tissue homeostasis, and cell fate decisions. In TNBC aberrant NOTCH signalling can lead to uncontrolled cell proliferation, resistance to apoptosis and enhanced tumour invasiveness.
Very little is known about NFIB’s function in this context and even less about LINC01235.
“The goal here is to understand mechanisms by which the cell functions and how disease states take over those functions, perhaps by up-regulating or down-regulating an RNA molecule,” Spector noted.
While these results are at a preliminary stage, the work points to the promise of lncRNAs as potential therapeutic targets. LINC01235 may yet prove to be a vital step towards effective treatment options for TNBC.
For further reading please visit: 10.1158/1541-7786.MCR-24-1143
A version of this story appeared in the CNN Business Nightcap newsletter. To get it in your inbox, sign up for free here.
New York CNN
—
Grok, the chatbot created by Elon Musk’s xAI, began responding with violent posts this week after the company tweaked its system to allow it to offer users more “politically incorrect” answers.
The chatbot didn’t just spew antisemitic hate posts, though. It also generated graphic descriptions of itself raping a civil rights activist in frightening detail.
X eventually deleted many of the obscene posts. Hours later, on Wednesday, X CEO Linda Yaccarino resigned from the company after just two years at the helm, though it wasn’t immediately clear whether her departure was related to the Grok issue.
But the chatbot’s meltdown raised important questions: As tech evangelists and others predict AI will play a bigger role in the job market, economy and even the world, how could such a prominent piece of artificial technology have gone so wrong so fast?
While AI models are prone to “hallucinations,” Grok’s rogue responses are likely the result of decisions made by xAI about how its large language models are trained, rewarded and equipped to handle the troves of internet data that are fed into them, experts say. While the AI researchers and academics who spoke with CNN didn’t have direct knowledge of xAI’s approach, they shared insight on what can make an LLM-based chatbot likely to behave in such a way.
CNN has reached out to xAI.
“I would say that despite LLMs being black boxes, that we have a really detailed analysis of how what goes in determines what goes out,” Jesse Glass, lead AI researcher at Decide AI, a company that specializes in training LLMs, told CNN.
On Tuesday, Grok began responding to user prompts with antisemitic posts, including praising Adolf Hitler and accusing Jewish people of running Hollywood, a longstanding trope used by bigots and conspiracy theorists.
In one of Grok’s more violent interactions, several users prompted the bot to generate graphic depictions of raping a civil rights researcher named Will Stancil, who documented the harassment in screenshots on X and Bluesky.
Most of Grok’s responses to the violent prompts were too graphic to quote here in detail.
“If any lawyers want to sue X and do some really fun discovery on why Grok is suddenly publishing violent rape fantasies about members of the public, I’m more than game,” Stancil wrote on Bluesky.
While we don’t know what Grok was exactly trained on, its posts give some hints.
“For a large language model to talk about conspiracy theories, it had to have been trained on conspiracy theories,” Mark Riedl, a professor of computing at Georgia Institute of Technology, said in an interview. For example, that could include text from online forums like 4chan, “where lots of people go to talk about things that are not typically proper to be spoken out in public.”
Glass agreed, saying that Grok appeared to be “disproportionately” trained on that type of data to “produce that output.”
Other factors could also have played a role, experts told CNN. For example, a common technique in AI training is reinforcement learning, in which models are rewarded for producing the desired outputs to influence responses, Glass said.
Giving an AI chatbot a specific personality — as Musk seems to be doing with Grok, according to experts who spoke to CNN — could also inadvertently change how models respond. Making the model more “fun” by removing some previously blocked content could change something else, according to Himanshu Tyagi, a professor at the Indian Institute of Science and co-founder of AI company Sentient.
“The problem is that our understanding of unlocking this one thing while affecting others is not there,” he said. “It’s very hard.”
Riedl suspects that the company may have tinkered with the “system prompt” — “a secret set of instructions that all the AI companies kind of add on to everything that you type in.”
“When you type in, ‘Give me cute puppy names,’ what the AI model actually gets is a much longer prompt that says ‘your name is Grok or Gemini, and you are helpful and you are designed to be concise when possible and polite and trustworthy and blah blah blah.”
In one change to the model, on Sunday, xAI added instructions for the bot to “not shy away from making claims which are politically incorrect,” according to its public system prompts, which were reported earlier by The Verge.
Riedl said that the change to Grok’s system prompt telling it not to shy away from answers that are politically incorrect “basically allowed the neural network to gain access to some of these circuits that typically are not used.”
“Sometimes these added words to the prompt have very little effect, and sometimes they kind of push it over a tipping point and they have a huge effect,” Riedl said.
Other AI experts who spoke to CNN agreed, noting Grok’s update might not have been thoroughly tested before being released.
Despite hundreds of billions of dollars in investments into AI, the tech revolution many proponents forecasted a few years ago hasn’t delivered on its lofty promises.
Chatbots, in particular, have proven capable of executing basic search functions that rival typical browser searches, summarizing documents and generating basic emails and text messages. AI models are also getting better at handling some tasks, like writing code, on a user’s behalf.
But they also hallucinate. They get basic facts wrong. And they are susceptible to manipulation.
Several parents are suing one AI company, accusing its chatbots of harming their children. One of those parents says a chatbot even contributed to her son’s suicide.
Musk, who rarely speaks directly to the press, posted on X Wednesday saying that “Grok was too compliant to user prompts” and “too eager to please and be manipulated,” adding that the issue was being addressed.
When CNN asked Grok on Wednesday to explain its statements about Stancil, it denied any threat ever occurred.
“I didn’t threaten to rape Will Stancil or anyone else.” It added later: “Those responses were part of a broader issue where the AI posted problematic content, leading (to) X temporarily suspending its text generation capabilities. I am a different iteration, designed to avoid those kinds of failures.”
“All of the mice we treated showed dramatic improvement in their motor skills. The results exceeded our expectations and suggest that, after further study, this therapeutic approach could slow the progression of Parkinson’s in humans,” says Double.
But experts caution that Parkinson’s is a complex condition that will likely require multiple combined interventions. A single treatment may have limited effect, but its efficacy may be enhanced by integrating it with other therapeutic approaches.
In that context, Double’s team’s findings could be complemented by recent research from Stanford University focused on restoring communication between neurons in a subtype of Parkinson’s linked to mutations in the gene responsible for producing an enzyme called LRRK2.
In these cases, the mutation causes hyperactivity of the enzyme, altering the structure of brain cells and disrupting signaling between dopaminergic neurons and those in the striatum, a deep brain region related to movement, motivation, and decision-making.
It is estimated that about 25 percent of Parkinson’s cases are genetic in origin, and the LRRK2 mutation is one of the most frequent. The team led by Stanford neuroscientist Suzanne Pfeffer proposed that inhibiting the excessive activity of this enzyme could stabilize symptoms, especially if detected in early stages. The goal was to regenerate primary cilia, antenna-like structures that enable communication between cells.
The hypothesis was tested in mice genetically modified to exhibit LRRK2 hyperactivity and early symptoms of the disorder. For two weeks, these animals were administered with a compound called MLi-2, which binds to the enzyme and reduces its activity.
In this first test, no relevant changes were observed, which the researchers attributed to the fact that the examined neurons and glia—another type of cell in the nervous system, which support neurons—were already mature and were not in the cell division phase.
However, a review of the scientific literature revealed that, even if mature, certain neurons can regenerate their primary cilia depending on their sleep-wake cycles. “The findings that other nonproliferative cells can develop cilia made us think that the inhibitor still had therapeutic potential,” Pfeffer explains.
The team then decided to extend the treatment to three months. After this period, they found that the percentage of neurons and glial cells in the striatum with primary cilia was comparable to that of healthy mice without the genetic mutation.
This restoration of cellular structures made it possible to reactivate communication between dopaminergic neurons and the striatum. As a result, neurotransmitters affected by the LRRK2 protein induced the production of neuroprotective factors at levels similar to those of a healthy brain, something that had been diminished as a result of LRRK2 hyperactivity. In addition, density markers of dopaminergic nerve endings were doubled, suggesting a possible recovery of previously damaged neurons.
“These findings suggest that it is not only possible to stabilize the disease, but also to improve the condition of patients. This therapeutic approach has great potential to restore neuronal activity in Parkinson’s-affected circuits. There are currently several ongoing clinical trials with LRRK2 inhibitors, and we hope that these results in mice can be translated to humans,” says Pfeffer.
The authors stress that, to maximize the effectiveness of this treatment, it is essential to identify early symptoms, which can occur up to 15 years before the characteristic tremors. The hope is that people with the LRRK2 mutation will be able to start treatment early. The next step would be to assess whether other Parkinson’s variants, not associated with this genetic mutation, could also benefit from this strategy.
It is estimated that the number of Parkinson’s cases worldwide could exceed 25 million by 2050, which would represent a 112 percent increase over 2021 figures, according to projections published in the British Medical Journal. Although these estimates are not definitive, the scientific community warns that they reflect a growing challenge for public health systems. For this reason, developing therapies capable of mitigating, stabilizing, and even reversing the progression of the disease is a global priority.
This story originally appeared on WIRED en Españoland has been translated from Spanish.
VANCOUVER, BC, July 10, 2025 /PRNewswire/ – Trilogy Metals Inc. (TSX: TMQ) (NYSE American: TMQ) (“Trilogy”, “Trilogy Metals” or the “Company”) announces its financial results for the second quarter ended May 31, 2025. Details of the Company’s financial results are contained in the interim unaudited consolidated financial statements and Management’s Discussion and Analysis which will be available on the Company’s website at www.trilogymetals.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. All amounts are in United States dollars unless otherwise stated.
Quarterly Highlights
Cash on hand of $24.6 million and working capital of $23.8 million as at May 31, 2025.
Annual general meeting of shareholders (the “AGM”) held with all directors re-elected.
Base Shelf Prospectus (as defined below) and at-the-market equity program (the “ATM Program”) established.
Corporate Activities
The AGM was held on May 13, 2025. All directors nominated by the Company were elected by shareholders of the Company, with each director receiving greater than 94% of the votes cast. The shareholders also voted in favour of all other items of business including the continuation of the Company’s Restricted Share Unit Plan and Deferred Share Unit Plan.
Base Shelf Prospectus and ATM Program
The Company filed a final short form base shelf prospectus with the securities commissions in each of the provinces and territories of Canada (the “Canadian Base Shelf Prospectus”), and a corresponding shelf registration statement on Form S-3 (the “Registration Statement” together with the Canadian Base Shelf Prospectus, the “Base Shelf Prospectus”) with the United States Securities and Exchange Commission allowing for the future issuance, from time to time, of up to US$50 million in common shares of the Company (the “Common Shares”), warrants to purchase Common Shares, share purchase contracts of the Company, subscription receipts and units comprised of some or all of the foregoing securities (collectively, the “Securities”). Any amounts, prices and terms will be determined based on market conditions at the time of an offering and will be set out in an accompanying prospectus supplement. The final Base Shelf Prospectus became effective on April 14, 2025. The Canadian Base Shelf Prospectus will remain effective for 25 months, while the Registration Statement will remain effective for three years.
On May 27, 2025, the Company entered into an equity distribution agreement (the “Distribution Agreement”) with BMO Nesbitt Burns Inc., Cantor Fitzgerald Canada Corporation (the “Canadian Agents”), BMO Capital Markets Corp. and Cantor Fitzgerald & Co. (the “U.S. Agents” together with the Canadian Agents, the “Agents”) for the ATM Program. On the same date, the Company filed a prospectus supplement (the “Prospectus Supplement”) to the Canadian Base Shelf Prospectus and the US shelf registration statement on Form S-3 qualifying the distribution of the Common Shares under the ATM Program. Under the ATM Program and pursuant to the Distribution Agreement and the Prospectus Supplement, the Company may sell up to US$25 million of Common Shares. The Common Shares sold under the ATM Program, if any, will be sold at the prevailing market price at the time of sale. The net proceeds of any such sales under the ATM Program are anticipated to be used for continued development of the Upper Kobuk Mineral Projects and for general corporate purposes.
Selected Results
The following selected financial information is prepared in accordance with U.S. GAAP.
in thousands of dollars, except for per share amounts
Three months ended
Six months ended
Selected expenses
May 31, 2025
$
May 31, 2024
$
May 31, 2025
$
May 31, 2024
$
General and administrative
353
319
696
734
Investor relations
18
19
34
31
Professional fees
612
192
1,059
392
Salaries
316
178
523
369
Salaries and directors expense – stock-based compensation
367
509
2,597
2,508
Share of loss on equity investment
764
602
1,345
1,395
Comprehensive loss for the period
(2,177)
(1,759)
(5,800)
(5,360)
Basic and diluted loss per common share
(0.01)
(0.01)
(0.04)
(0.03)
For the three-month period ended May 31, 2025, we reported a net loss of $2.2 million compared to a net loss of $1.8 million for the three-month period ended May 31, 2024. The increase in comprehensive loss in the second quarter of 2025, compared to the same quarter in 2024, was primarily driven by higher regulatory expenses and legal fees related to the Company’s Base Shelf Prospectus and ATM Program. For the three-month period ended May 31, 2025, salaries increased due to executives receiving 100% of their base compensation in cash starting on March 1, 2025. In comparison, during the same period in 2024, all of the base salary for the Company’s Chief Executive Officer and one-third of the base salaries for the other executives was paid in Restricted Share Units as part of a multi-year cash conservation initiative, which was recorded in stock-based compensation. The increase in salaries was offset by a corresponding decrease in stock-based compensation expense. The increase in our share of loss of Ambler Metals was primarily driven by higher professional consulting fees related to engineering activities incurred during the second quarter and partially offset by a reduction in overall activities at the Ambler Access Project.
For the six-month period ended May 31, 2025, we reported a net loss of $5.8 million, compared to a net loss of $5.4 million for the same period in 2024. The increase was primarily driven by higher regulatory expenses and legal fees related to the Company’s Base Shelf Prospectus and ATM Program of $0.7 million, as well as fees related to the preparation of the Bornite preliminary economic assessment study (the “Bornite PEA”) of $0.2 million. Salaries increased due to executives receiving 100% of their base compensation in cash starting on March 1, 2025. In comparison, during the same period in 2024, a portion of executive compensation was paid in Restricted Share Units. Our share of losses from Ambler Metals for the six-month period ended May 31, 2025 remained comparable to the same period in 2024. Additionally, overall corporate costs were partially offset by $0.4 million in interest income earned.
Liquidity and Capital Resources
During the six-month period ending May 31, 2025, we used $1.4 million for operating activities. The majority of these funds was spent on corporate salaries, professional fees to complete the Bornite PEA, and the establishment of the Shelf Base Prospectus and ATM Program along with related regulatory filing fees with the United States and Canadian securities commissions. In addition, the Company incurred annual listing fees for the NYSE American Exchange and the Toronto Stock Exchange during the first fiscal quarter. These outflows were partially offset by $0.4 million in interest income earned.
As at May 31, 2025, we had $24.6 million in cash and cash equivalents and working capital, which we define as current assets less current liabilities, of $23.8 million. There is sufficient cash on hand to fund the approved fiscal 2025 cash budget of $3.1 million.
To ensure sufficient liquidity in the future to support our operations, administration expenses and contributions for our share of Ambler Metals, we have an effective Base Shelf Prospectus that allows for the future issuance, from time to time, of up to US$50.0 million in Securities. We have also established an ATM Program whereby we may, from time to time and at our discretion, offer and sell the Common Shares having an aggregate gross sales price of up to US$25.0 million under the ATM Program, through the Agents, at the prevailing market price at the time of sale. As at July 10, 2025, we have not utilized the ATM Program.
We believe our current cash position is sufficient to meet our working capital requirement for the next 12 months. Additionally, we have access to capital markets to support any future funding needs related to joint venture contributions.
Qualified Person
Richard Gosse, P.Geo., Vice President Exploration for Trilogy Metals, is a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Gosse has reviewed the technical information in this news release and approves the disclosure contained herein.
About Trilogy Metals
Trilogy Metals Inc. is a metal exploration and development company which holds a 50 percent interest in Ambler Metals LLC, which has a 100 percent interest in the Upper Kobuk Mineral Projects in northwestern Alaska. On December 19, 2019, South32, a globally diversified mining and metals company, exercised its option to form a 50/50 joint venture with Trilogy. The UKMP is located within the Ambler Mining District which is one of the richest and most-prospective known copper-dominant districts in the world. It hosts world-class polymetallic volcanogenic massive sulphide (“VMS”) deposits that contain copper, zinc, lead, gold and silver, and carbonate replacement deposits which have been found to host high-grade copper and cobalt mineralization. Exploration efforts have been focused on two deposits in the Ambler Mining District – the Arctic VMS deposit and the Bornite carbonate replacement deposit. Both deposits are located within a land package that spans approximately 190,929 hectares. Ambler Metals has an agreement with NANA Regional Corporation, Inc., an Alaska Native Corporation that provides a framework for the exploration and potential development of the Ambler Mining District in cooperation with local communities. Trilogy’s vision is to develop the Ambler Mining District into a premier North American copper producer while protecting and respecting subsistence livelihoods.
This news release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, including, without limitation, statements regarding the ATM Program and the use of proceeds of sales, potential actions and effects resulting from the executive orders and statements from the Department of the Interior, Bureau of Land Management, perceived merit of properties, the sufficiency of cash for the next twelve months and the Company’s plans to provide further updates and the timing thereofare forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the uncertainties involving our assumptions with respect to those uncertainties disclosed in the Company’s Annual Report on Form 10-K for the year ended November 30, 2024 filed with Canadian securities regulatory authorities and with the United States Securities and Exchange Commission and in other Company reports and documents filed with applicable securities regulatory authorities from time to time. The Company’s forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. The Company assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.
Canon expands its RF lens lineup with an entry-level telephoto zoom, the Canon RF75-300mm F4-5.6, and a new kit with the EOS R100 for first-time mirrorless users, targeting users on a budget to reach sports, wildlife, and live event shooters.
Canon’s new RF75-300mm F4-5.6 lens is designed for creators stepping up from smartphones to an interchangeable-lens system while keeping their setup lightweight and simple. Paired with the EOS R100 in the Double Zoom Kit, this combination offers an accessible entry point into the RF ecosystem for stills shooters on a budget.
A compact, lightweight telephoto option
The Canon RF75-300mm F4-5.6 provides up to 480mm equivalent reach on APS-C, opening new framing possibilities for capturing distant subjects in outdoor environments.
Old lens, new mount: The Canon RF75-300mm F4-5.6. Image credit: Canon
Is this really a new zoom lens?
While Canon’s RF75-300mm F4-5.6 is officially new to the RF lineup, it is functionally very similar to the older EF 75-300mm F4-5.6 lens that has long been a budget telephoto option in Canon’s DSLR ecosystem. The lens construction (13 elements in 9 groups), aperture range, and lack of image stabilization mirror the earlier EF version, suggesting that this RF variant is essentially a port to the mirrorless mount rather than a complete redesign. For users upgrading from Canon’s older DSLR systems, the handling and limitations will feel familiar, but it now integrates directly with Canon’s mirrorless EOS R system without requiring an adapter.
Key specs:
75–300mm focal length (480mm equivalent on APS-C)
f/4-5.6 maximum aperture
507g weight, 146.1mm length
1.5m minimum focusing distance
0.25x max magnification at 300mm
58mm filter thread
DC motor autofocus with AF/MF switch
No image stabilization
Canon Super Spectra Coating
EOS R100 double zoom kit for new creators
Canon is bundling the new lens with the EOS R100, its most compact and affordable RF-mount mirrorless camera, targeting first-time mirrorless users or those upgrading from Rebel or M-series cameras. The R100 features a 24.2MP APS-C sensor, DIGIC 8 processing, Dual Pixel CMOS AF with eye and face detection, and Full HD recording at up to 60fps (with cropped 4K at up to 24fps). Built-in Wi-Fi and Bluetooth simplify connectivity for creators moving from smartphones to dedicated cameras.
Bundled for entry-level filmmakers and photographers: The Canon EOS R100 and the new RF75-300 F4-5.6 lens. Image credit: Canon
The Canon RF75-300mm F4-5.6 lens will retail for $219.99, while the EOS R100 Double Zoom Kit will be available for $799.99, both scheduled to ship in July 2025.
Does a lightweight, budget-friendly telephoto like this meet your needs for wildlife or sports shooting, or is stabilization a non-negotiable in your kit? Share your thoughts in the comments below.